{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:54:59Z","timestamp":1783137299325,"version":"3.54.6"},"reference-count":19,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The single-arm phase II APT trial established trastuzumab and paclitaxel (TH) as the standard adjuvant regimen for small human epidermal growth factor receptor 2 (HER2+) tumors. However, paclitaxel causes alopecia and has high rates of neuropathy and hypersensitivity reactions. In patients with metastatic HER2+ breast cancer (BC), the combination of trastuzumab and vinorelbine (TV) is effective and well tolerated. There is a need for alternative non-anthracycline\/taxane-based regimens for patients with HER2+ early-stage BC, especially for those with contraindications or who wish to avoid side effects of taxane-based regimens. Here we describe our institutional experience with adjuvant TV for patients with early-stage HER2+ BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Clinicopathological characteristics, treatment details, and outcomes of patients with localized HER2+ BC treated with adjuvant TV from 2007 to 2021 at a large academic medical institution were collected. Study endpoints included invasive disease-free survival (IDFS), overall survival (OS), and safety\/tolerability. IDFS and OS were measured from start date of TV treatment to date of event\/last follow-up and date of death\/last follow-up, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 30 patients were treated with TV. All patients received trastuzumab at standard dosing and vinorelbine at a starting dose of 25\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      either on days 1\/8 or on days 1\/8\/21 (weekly) of a 21-day cycle with four planned cycles. Median age at diagnosis was 59\u2009years (range: 36\u201381). 90.3% of patients had anatomic pathologic stage IA BC and 9.7% stage IIA BC. Of the 30 patients, 24 of them opted to pursue TV due to concerns related to alopecia, neuropathy, and other toxicities, and 6 switched from treatment with TH to TV due to toxicities. Eight patients experienced neutropenia with no cases of febrile neutropenia. No patients experienced alopecia or long-term neuropathy. With a median follow-up of 68\u2009months (5.7\u2009years), the 5-year IDFS rate was 90.9%, with one local and one distant recurrence. The 5-year OS was 100%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Trastuzumab in combination with vinorelbine in the adjuvant, early-stage setting for low-risk HER2+ BC demonstrated clinical efficacy and appeared to be well tolerated. TV warrants further evaluation as an alternative regimen to TH for patients with early-stage HER2+ BC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359221146133","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T01:05:10Z","timestamp":1673399110000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer"],"prefix":"10.1177","volume":"15","author":[{"given":"Shannon","family":"McLaughlin","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Bar","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Shin","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Moy","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Isakoff","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4885-1157","authenticated-orcid":false,"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kuter","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8904-3514","authenticated-orcid":false,"given":"Laura M.","family":"Spring","sequence":"additional","affiliation":[{"name":"Attending Physician, Massachusetts General Hospital Cancer Center, Harvard Medical School, Bartlett Hall, 40R Blossom St., Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"bibr1-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2385-z"},{"key":"bibr2-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/12.suppl_1.S57"},{"key":"bibr3-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3857-5"},{"key":"bibr4-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"bibr5-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30570-9"},{"key":"bibr6-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt182"},{"key":"bibr7-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406281"},{"key":"bibr8-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00066"},{"key":"bibr9-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03398"},{"key":"bibr10-17588359221146133","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2010.n.065"},{"key":"bibr11-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22885"},{"key":"bibr12-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.10.2722"},{"key":"bibr13-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0773-6"},{"key":"bibr14-17588359221146133","doi-asserted-by":"publisher","DOI":"10.3747\/co.21.2069"},{"key":"bibr15-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2011.23.1.32"},{"key":"bibr16-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03613"},{"key":"bibr17-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1002\/pon.1615"},{"key":"bibr18-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1002\/pon.1245"},{"key":"bibr19-17588359221146133","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1557"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359221146133","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359221146133","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359221146133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:28:02Z","timestamp":1777588082000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359221146133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":19,"alternative-id":["10.1177\/17588359221146133"],"URL":"https:\/\/doi.org\/10.1177\/17588359221146133","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"17588359221146133"}}